|Bid||22.02 x 1100|
|Ask||22.67 x 1200|
|Day's Range||22.02 - 22.30|
|52 Week Range||11.60 - 45.82|
|Beta (5Y Monthly)||1.72|
|PE Ratio (TTM)||N/A|
|Earnings Date||Nov. 08, 2021 - Nov. 12, 2021|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||38.00|
HAYWARD, Calif., October 05, 2021--Pulse Biosciences, Inc. (Nasdaq: PLSE), a novel bioelectric medicine company commercializing the CellFX® System powered by Nano-Pulse Stimulation™ (NPS™) technology, today announced the appointment of Laureen DeBuono to its Board of Directors. Concurrent to Ms. DeBuono’s appointment, Kenneth Clark has resigned from the Board of Directors.
HAYWARD, Calif., September 02, 2021--Pulse Biosciences, Inc. (Nasdaq: PLSE), a novel bioelectric medicine company introducing the CellFX® System powered by Nano-Pulse Stimulation™ (NPS™) technology, today announced plans to participate in the upcoming virtual H.C. Wainwright Global Investment Conference.
David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...